c-mos immunoreactivity is an indicator of good prognosis in lung cancer.
Athanasiou A, Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Liloglou T, Karameris A, Foukas P, Manolis EN, Field JK, Kittas C.
Athanasiou A, et al. Among authors: mariatos g.
Histopathology. 2000 Jul;37(1):45-54. doi: 10.1046/j.1365-2559.2000.00898.x.
Histopathology. 2000.
PMID: 10931218